AstraZeneca
AmoyDx, AstraZeneca Partner on HER2 Lung Cancer CDx Development in China
Amoy will develop a companion diagnostic for Enhertu (trastuzumab deruxtecan) under its latest agreement to develop companion diagnostics for AstraZeneca's therapies.
Amoy Diagnostics, AstraZeneca Partner to Advance PARP Inhibitor CDx For Maintenance Indication
AmoyDx's test, if approved, would identify patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who are eligible for maintenance treatment.
Tempus, AstraZeneca Partner to Study NSCLC Biology in GEMINI Trial
Researchers will molecularly profile patients' tumors and track over three years how their tumor biology changes as their disease progresses and they receive treatment.
IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership
Following an evaluation of the Korean firm's test, the two companies are partnering to increase awareness among clinicians and patients.
Top Five Articles on 360Dx Last Week: Mobile Phlebotomy Company Fraud; Quest, Agilent Deal; and More
Last week, readers were most interested in a guilty plea by a mobile phlebotomy company alleged to have engaged in a $7.5 million scheme.